Genesis BioSystems is a venture-backed start-up that has developed a potentially revolutionary alternative to in-vitro fertilization. Before bringing the product to market, Genesis must achieve several key milestones, including the FDA’s approval. The product’s most recent tests were disappointing, but perhaps human embryos will produce a better study than mouse embryos. The decision to initiate human clinical trials will have enormous consequences for the company’s future, and Genesis’s CEO must come to an agreement with the board of directors on how to proceed.
Genesis BioSystems: The Board Weighs In on Product Development Setbacks
by: Tom Porter
Core Disciplines: Entrepreneurship & Innovation
Click on any button below to view the available document.
Make sure you are registered and/or logged in to our site to view product documents. Once registered & approved, faculty, staff, & course aggregators will have access to full inspection copies and teaching notes for any of our materials.
If you need to make copies, you MUST purchase the corresponding number of permissions, and you must own a single copy of the product.
Electronic Downloads are available immediately after purchase. "Quantity" reflects the number of copies you intend to use. Unauthorized distribution of these files is prohibited pursuant to term of use of this website.
This product has a teaching note available. Available only to Registered Educators. Please login to view it.
After reading and discussing the material, students should:
- Determine the role of the boards of directors for early-stage companies.
- Describe the role of a CEO, specifically as it relates to the board of directors.
- Asses how venture capitalists and other investors can add value.
- Practice strategic planning for medical device companies.